Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
BACKGROUND Cancer immunotherapy has changed the standard of care for a subgroup of patients with advanced disease. Immune checkpoint blockade (ICB) in particular has shown improved survival compared with previous standards of care for several tumor types. Although proven to be successful in more immunogenic tumors, ICB is still largely ineffective in patients with tumors that are not infiltrated by immune cells, the so-called cold tumors. PATIENTS AND METHODS This review describes the effects of different chemotherapeutic agents on the immune system and the potential value of these different types of chemotherapy as combination partners with ICB in patients with solid tumors. Both preclinical data and currently ongoing clinical trials were evaluated. In addition, we reviewed findings regarding different dosing schedules, including the effects of an induction phase and applying metronomic doses of chemotherapy. RESULTS Combining ICB with other treatment modalities may lead to improved immunological conditions in the tumor microenvironment and could thereby enhance the antitumor immune response, even in tumor types that are so far unresponsive to ICB monotherapy. Chemotherapy, that was originally thought to be solely immunosuppressive, can exert immunomodulatory effects which may be beneficial in combination with immunotherapy. Each chemotherapeutic drug impacts the tumor microenvironment differently, and in order to determine the most suitable combination partners for ICB it is crucial to understand these mechanisms. CONCLUSION Preclinical studies demonstrate that the majority of chemotherapeutic drugs has been shown to exert immunostimulatory effects, either by inhibiting immunosuppressive cells and/or activating effector cells, or by increasing immunogenicity and increasing T-cell infiltration. However, for certain chemotherapeutic agents timing, dose and sequence of administration of chemotherapeutic agents and ICB is important. Further studies should focus on determining the optimal drug combinations, sequence effects and optimal concentration-time profiles in representative preclinical models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“It is thought that ICB has the highest likelihood of success in tumors that have an inflamed phenotype [44, 45].”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 3×
“[24] PD-L1 expression on TILs correlates with response Various tumor types Atezolizumab, pembrolizumab Herbst et al.”
BackgroundPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Currently, three combinations have been approved for first-line treatment, all for advanced NSCLC [120, 147, 148].”
BackgroundNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“These two phenotypes rarely respond to ICB monotherapy [19].”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“[126] Combination therapy resulted into a higher OS (11.”
BackgroundGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 1×
“[16] Mismatch repair status Mismatch repair deficiency correlates with response Any solid tumor with mismatch repair deficiency Pembrolizumab Le et al.”
BackgroundPembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617 · cited 1×
“Currently, three combinations have been approved for first-line treatment, all for advanced NSCLC [120, 147, 148].”
BackgroundFirst-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · cited 1×
“[41] Upregulated T-helper type 1 gene expression at baseline correlates to response Various Atezolizumab Herbst et al.”
BackgroundWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K.-M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,654
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · cited 1×
“Inhibition of caspase, or depletion of DCs or CD8þ T-cells may abolish anthracycline-mediated antitumor immune response [63].”
BackgroundPembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“For instance, anthracyclines are able to elicit an immune response in a similar manner as induced by viral pathogens [64].”
BackgroundLynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541 · cited 3×
“[10] Low leukocyte count at baseline correlates with response Melanoma Ipilimumab Gebhardt et al.”
BackgroundHamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8023 · Cited by 516
Bagley, S. J., Kothari, S., Aggarwal, C., Bauml, J. M., Alley, E. W., Evans, T. L., Kosteva, J. A., Ciunci, C. A., Gabriel, P. E., Thompson, J. C., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.013 · Cited by 511
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
Ahlmann, M., & Hempel, G. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3152-1 · Cited by 499
Prat, A., Navarro, A., Paré, L., Reguart, N., Galván, P., Pascual, T., Martínez, A., Nuciforo, P., Comerma, L., Alos, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3556 · Cited by 455
Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S., Chow, L. Q., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 445
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw016 · Cited by 395
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Govindan, R., Szczesna, A., Ahn, M.-J., Schneider, C.-P., Gonzalez Mella, P. F., Barlesi, F., Han, B., Ganea, D. E., Von Pawel, J., Vladimirov, V., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7629 · Cited by 365
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Sul, J., Blumenthal, G. M., Jiang, X., He, K., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0498 · Cited by 359
Liu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 356
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · cited 2×
“In contrast, another study found no effect, [72], while others even found that taxane treatment led to increased NK and lymphokine activated killer cell activity [73].”
BackgroundResultCytokines in immunogenic cell death: Applications for cancer immunotherapy
Showalter, A., Limaye, A., Oyer, J. L., Igarashi, R., Kittipatarin, C., Copik, A. J., & Khaled, A. R. (2017) · Cytokine · doi:10.1016/j.cyto.2017.05.024 · Cited by 319
Hersh, E. M., O’Day, S. J., Powderly, J., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S. (2011) · Investigational New Drugs · doi:10.1007/s10637-009-9376-8 · Cited by 307
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Demaria, S., Volm, M., Shapiro, R. L., Yee, H. T., Oratz, R., Formenti, S. C., Muggia, F. M., & Symmans, W. F. (2001) · PubMed · Cited by 303
Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295 · cited 1×
“Tumor cells surviving topotecan treatment have upregulated major histocompatibility complex I (MHCI) and Fas expression, making them more sensitive to effector T-cell killing [56, 57].”
BackgroundChemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1545-8 · Cited by 253
Vilain, R. E., Menzies, A. M., Wilmott, J. S., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B. Y., Cooper, A. J., Howle, J. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0698 · Cited by 245
Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., Blumenstein, M., Thum, J., Sohn, C., Schneeweiss, A., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1106-3 · Cited by 228
Aglietta, M., Barone, C., Sawyer, M. B., Moore, M. J., Miller, W. H., Bagalà, C., Colombi, F., Cagnazzo, C., Gioeni, L., Wang, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu205 · Cited by 219
Zhang, L., Dermawan, K., Jin, M., Liu, R., Zheng, H., Xu, L., Zhang, Y., Cai, Y., Chu, Y., & Xiong, S. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.013 · Cited by 209
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3001 · Cited by 201
Tran, L., Allen, C. T., Xiao, R., Moore, E., Davis, R., Park, S.-J., Spielbauer, K., Van Waes, C., & Schmitt, N. C. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0235 · Cited by 186
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Roselli, M., Cereda, V., di Bari, M. G., Formica, V., Spila, A., Jochems, C., Farsaci, B., Donahue, R., Gulley, J. L., Schlom, J., et al. (2013) · OncoImmunology · doi:10.4161/onci.27025 · Cited by 182
Loi, S., Adams, S., Schmid, P., Cortés, J., Cescon, D. W., Winer, E. P., Toppmeyer, D. L., Rugo, H. S., De Laurentiis, M., Nanda, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.005 · Cited by 181
Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., Abe, T., Funakoshi, T., Yamamoto, N., Amagai, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12677 · Cited by 164
Li, J.-Y., Duan, X.-F., Wang, L.-P., Xu, Y.-J., Huang, L., Zhang, T.-F., Liu, J.-Y., Li, F., Zhang, Z., Yue, D.-L., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/286170 · Cited by 157
Kaneno, R., Shurin, G. V., Tourkova, I. L., & Shurin, M. R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-58 · Cited by 155
Anticancer metal drugs and immunogenic cell death
Terenzi, A., Pirker, C., Keppler, B. K., & Berger, W. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.06.021 · Cited by 151
Lesterhuis, W. J., Salmons, J., Nowak, A. K., Rozali, E. N., Khong, A., Dick, I. M., Harken, J. A., Robinson, B. W., & Lake, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061895 · Cited by 145
Ning, Y. M., Suzman, D. L., Maher, V. E., Zhang, L., Tang, S. W., Ricks, T. K., Palmby, T. R., Fu, W., Liu, Q., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0087 · Cited by 142
Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134
Kitano, S., Postow, M. A., Ziegler, C. G. K., Kuk, D., Panageas, K. S., Cortez, C., Rasalan, T., Adamow, M., Yuan, J., Wong, P., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0013 · Cited by 134
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Weiss, G. J., Waypa, J., Blaydorn, L., Coats, J., McGahey, K., Sangal, A., Niu, J., Lynch, C. A., Farley, J. H., & Khemka, V. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.145 · Cited by 130
Yamazaki, N., Kiyohara, Y., Uhara, H., Iizuka, H., Uehara, J., Otsuka, F., Fujisawa, Y., Takenouchi, T., Isei, T., Iwatsuki, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13226 · Cited by 126
Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Molinero, L., He, X., Waterkamp, D., Funke, R. P., & Powderly, J. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.1009 · Cited by 126
Galsky, M. D., Wang, H., Hahn, N. M., Twardowski, P. W., Pal, S. K., Albany, C., Fleming, M. T., Starodub, A., Hauke, R. J., Yu, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.12.001 · Cited by 122
Paz-Ares, L. G., Luft, A., Tafreshi, A., Gumus, M., Mazieres, J., Hermes, B., Cay Senler, F., Fülöp, A., Rodriguez-Cid, J., Sugawara, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.105 · Cited by 121
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wang, W., Yu, D., Sarnaik, A. A., Yu, B., Hall, M., Morelli, D., Zhang, Y., Zhao, X., & Weber, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-146 · Cited by 120
Audia, S., Nicolas, A., Cathelin, D., Larmonier, N., Ferrand, C., Foucher, P., Fanton, A., Bergoin, E., Maynadie, M., Arnould, L., et al. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03521.x · Cited by 119
Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model
Matar, P., Rozados, V. R., Gervasoni, S. I., & Scharovsky, O. G. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-001-0237-3 · Cited by 119
Medina‐Echeverz, J., Fioravanti, J., Zabala, M., Ardaiz, N., Prìeto, J., & Berraondo, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001483 · Cited by 114
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Morello, S., Capone, M., Sorrentino, C., Giannarelli, D., Madonna, G., Mallardo, D., Grimaldi, A. M., Pinto, A., & Ascierto, P. A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1348-8 · Cited by 107
Chemotherapy Broadens the Range of Tumor Antigens Seen by Cytotoxic CD8+ T Cells in Vivo
Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1307-4 · Cited by 105
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Cassidy, M. R., Wolchok, R. E., Zheng, J., Panageas, K. S., Wolchok, J. D., Coit, D., Postow, M. A., & Ariyan, C. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.029 · Cited by 104
Immunomodulation in cancer therapeutics
Ehrke, M. J. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(03)00021-3 · Cited by 101
Yu, Y., & Lee, N. Y. (2018) · Future Oncology · doi:10.2217/fon-2018-0405 · Cited by 97
Kanda, S., Goto, K., Shiraishi, H., Kubo, E., Tanaka, A., Utsumi, H., Sunami, K., Kitazono, S., Mizugaki, H., Horinouchi, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw416 · Cited by 93
Tietze, J. K., Angelova, D., Heppt, M. V., Reinholz, M., Murphy, W. J., Spannagl, M., Ruzicka, T., & Berking, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.031 · Cited by 91
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
McKenzie, J. A., Mbofung, R. M., Malu, S., Zhang, M., Ashkin, E., Devi, S., Williams, L., Tieu, T., Peng, W., Pradeep, S., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx257 · Cited by 91
Ock, C.-Y., Kim, S., Keam, B., Kim, S., Ahn, Y., Chung, E., Kim, J.-H., Kim, T. M., Kwon, S. K., Jeon, Y. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18542 · Cited by 90
Schmid, P., Park, Y. H., Muñoz-Couselo, E., Kim, S.-B., Sohn, J., Im, S.-A., Holgado, E., Wang, Y., Dang, T., Aktan, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.556 · Cited by 89
Homma, Y., Taniguchi, K., Nakazawa, M., Matsuyama, R., Mori, R., TAKEDA, K., Ichikawa, Y., Tanaka, K., & Endo, I. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1079-0 · Cited by 86
Ferraro‐Peyret, C., Quéméneur, L., Fournel, S., Prigent, A.-F., Révillard, J. P., & Bonnefoy, N. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400595 · Cited by 73
Galetto, A., Buttiglieri, S., Forno, S., Moro, F., Mussa, A., & Matera, L. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200311000-00010 · Cited by 73
Bang, Y., Muro, K., Fuchs, C. S., Golan, T., Geva, R., Hara, H., Jalal, S. I., Borg, C., Doi, T., Wainberg, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4012 · Cited by 73
Tolaney, S., Kalinsky, K., Kaklamani, V, Savulsky, C., Olivo, M., Aktan, G., Kaufman, P., Xing, D., Almonte, A., Misir, S., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd6-13 · Cited by 71
Loibl, S., Untch, M., Burchardi, N., Huober, J., Blohmer, J., Grischke, E., Furlanetto, J., Tesch, H., Hanusch, C. A., Rezai, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.104 · Cited by 70
Scurr, M., Pembroke, T., Bloom, A., Roberts, D., Thomson, A., Smart, K., Bridgeman, H., Adams, R., Brewster, A., Jones, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2579 · Cited by 68
Adriamycin-induced modulation of host defenses in tumor-bearing mice.
Maccubbin, D., Wing, K. R., Mace, K. F., et al. (1992) · PubMed · Cited by 65
Huang, X., Cui, S., & Shu, Y. (2015) · Immunologic Research · doi:10.1007/s12026-015-8734-1 · Cited by 64
Hu, J., Kinn, J., Zirakzadeh, A. A., Sherif, A., Norstedt, G., Wikström, A.-C., & Winqvist, O. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12060 · Cited by 61
Wang, W., Wu, L., Zhang, J., Wu, H., Han, E.-K., & Guo, Q. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.180 · Cited by 61
Quartino, A. L., Friberg, L. E., & Karlsson, M. O. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9603-3 · Cited by 58
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Alagkiozidis, I., Facciabene, A., Tsiatas, M., Carpenito, C., Benencia, F., Adams, S., Jonak, Z., June, C. H., Powell, D. J., & Coukos, G. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-77 · Cited by 55
Cellular Immune Profile of Patients With Advanced Cancer Before and After Taxane Treatment
Tong, A. W., Seamour, B., Lawson, J. M., Ordóñez, G., Vukelja, S. J., Hyman, W. J., Richards, D., Stein, L., Maples, P. B., & Nemunaitis, J. J. (2000) · American Journal of Clinical Oncology · doi:10.1097/00000421-200010000-00007 · Cited by 54
Dacarbazine in Melanoma: From a Chemotherapeutic Drug to an Immunomodulating Agent
Ugurel, S., Paschen, A., & Becker, J. C. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.341 · Cited by 52
Tel, J., Hato, S. V., Torensma, R., Buschow, S. I., Figdor, C. G., Lesterhuis, W. J., & de Vries, I. J. M. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1189-x · Cited by 51
Liu, S. V., Camidge, D. R., Gettinger, S. N., Giaccone, G., Heist, R. S., Hodi, F. S., Ready, N., Zhang, W., Wallin, J. J., Funke, R. P., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.033 · Cited by 51
Cottu, P. H., D’Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P., Duhoux, F. P., Lévy, C., Mouret-Reynier, M.-A., Dalenc, F., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440 · Cited by 50
Chuang, L. T., Lotzová, E., Heath, J., Cook, K. R., Munkarah, A. R., Morris, M., & Wharton, J. T. (1994) · PubMed · Cited by 49
Frey, B., Stache, C., Rubner, Y., Werthmöller, N., Schulz, K., Sieber, R., Semrau, S., Rödel, F., Fietkau, R., & Gaipl, U. S. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.693547 · Cited by 48
Wu, J., Jordan, M., & Waxman, D. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2597-2 · Cited by 47
Reck, M., Socinski, M. A., Cappuzzo, F., Orlandi, F., Stroyakovskii, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., Thomas, C. A., Barlési, F., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx760.002 · Cited by 45
PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
Sclafani, F. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30512-0 · Cited by 44
Iida, Y., Harashima, N., Motoshima, T., Komohara, Y., Eto, M., & Harada, M. (2017) · Cancer Science · doi:10.1111/cas.13337 · Cited by 44
Ayers, M., Lunceford, J. K., Nebozhyn, M., Murphy, E., Loboda, A. P., Albright, A. V., Cheng, J. D., Kang, S. P., Ebbinghaus, S., Yearley, J. H., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p80 · Cited by 43
Sakai, H., Kokura, S., Ishikawa, T., Tsuchiya, R., Okajima, M., Matsuyama, T., Adachi, S., Katada, K., Kamada, K., Uchiyama, K., et al. (2012) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.12-60 · Cited by 41
Haggerty, T. J., Dunn, I. S., Rose, L. B., Newton, E. E., Martin, S., Riley, J. L., & Kurnick, J. T. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0926-x · Cited by 36
Gray, A., García-Hernández, M. D. L. L., van West, M., Kanodia, S., Hubby, B., & Kast, W. M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.106 · Cited by 36
Cui, S. (2017) · Medical Science Monitor · doi:10.12659/msm.902426 · Cited by 33
Higgs, B. W., Robbins, P. B., Blake-Haskins, J. A., Zhu, W., Morehouse, C., Brohawn, P. Z., Rebelatto, M. C., Yao, Y., Jin, X., Shi, L., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31937-2 · Cited by 32
Nio, Y., Hirahara, N., Minari, Y., Iguchi, C., Yamasawa, K., Toga, T., & Tamura, K. (2000) · PubMed · Cited by 27
Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages
Fujimura, T., Kakizaki, A., Kambayashi, Y., Sato, Y., Tanita, K., Lyu, C., Furudate, S., & Aiba, S. (2017) · Experimental Dermatology · doi:10.1111/exd.13417 · Cited by 25
Fujimoto, N., Aoe, K., Kozuki, T., Oze, I., Kato, K., Kishimoto, T., & Hotta, K. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.001 · Cited by 25
Kwa, M. J., Li, X., Novik, Y., Oratz, R., Jhaveri, K. L., Wu, J. J., Gu, P., Meyers, M. I., Muggia, F. M., Speyer, J. L., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4570-4 · Cited by 24
Kok, M., Horlings, H. M., de Vijver, K. K. V., Wiersma, T., Russell, N. S., Voorwerk, L., Sikorska, K., van Werkhoven, E. D., Mandjes, I. A. M., Kemper, I., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.006 · Cited by 23
Self-citationKashima, H., Momose, F., Umehara, H., Miyoshi, N., Ogo, N., Muraoka, D., Shiku, H., Harada, N., & Asai, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156643 · Cited by 22
Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy
Tietze, J. K., Angelova, D., Heppt, M. V., Ruzicka, T., & Berking, C. (2016) · Experimental Dermatology · doi:10.1111/exd.13263 · Cited by 21
Parikh, M., Pan, C.-X., Beckett, L. A., Li, Y., Robles, D., Aujla, P. K., & Lara, P. N. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.004 · Cited by 15
Changes in T lymphocyte subsets after single dose epirubicin
Lissoni, P., Tancini, G., Archili, C., Rescaldani, R., Cattaneo, G., Crispino, S., & Barni, S. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90142-g · Cited by 6
Vida, A. R., Mellado, B., del Muro, X. G., Taus, Á., Morales‐Barrera, R., Maroto, P., Bonfill, T., Domènech, M., Pinto, Á., Valderrama, B. P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps4591 · Cited by 5
Stage as major long term outcome predictor in minor salivary gland carcinoma
Lutgendorf (2000) · Pure Amsterdam UMC · doi:10.1002/1097-0142(20000915)89:6 · Cited by 1
Cited by
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687
“Chemotherapy was previously thought to be solely immunosuppressive, but data show that the majority of chemotherapeutic drugs have immunostimulatory properties, either by inhibiting immunosuppressive cells and/or activating effector cells, or by increasing immunogenicity and T-cell infiltration.(99) Indeed, the combin…”
BackgroundImmune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
“265 Radiotherapy combined with ICB Radiotherapy can cause DNA damage-induced tumour cell death, regulate the immunogenicity of tumour cells, expose immunogenic mutations, enhance the expression of neoantigens and increase tumour in fi ltration of immunostimulatory cells.”
BackgroundHuang, J., Liu, D., Wang, Y., Liu, L., Li, J., Yuan, J., Jiang, Z., Jiang, Z., Hsiao, W. W., Liu, H., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-321031 · Cited by 539
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
Metadata
- Authors
- Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 30
- Issue
- 2
- Pages
- 219-235
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2906932524
- Cited by
- 557
- References
- 137
- FWCI
- 20.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.